Per Rathenborg

1.7k total citations · 1 hit paper
18 papers, 1.1k citations indexed

About

Per Rathenborg is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Per Rathenborg has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 10 papers in Cancer Research and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Per Rathenborg's work include Prostate Cancer Treatment and Research (15 papers), Cancer, Lipids, and Metabolism (9 papers) and Hormonal and reproductive studies (5 papers). Per Rathenborg is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), Cancer, Lipids, and Metabolism (9 papers) and Hormonal and reproductive studies (5 papers). Per Rathenborg collaborates with scholars based in Denmark, United States and Netherlands. Per Rathenborg's co-authors include Neal D. Shore, Fred Saad, De Phung, Andrew Krivoshik, Eren Demirhan, Maha Hussain, Karim Fizazi, Katharina Modelska, Cora N. Sternberg and Ubirajara Ferreira and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Per Rathenborg

17 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

2018 677 citations Maha Hussain, Karim Fizazi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Per Rathenborg Denmark	11	923	325	309	308	204	18	1.1k
S. Chowdhury United Kingdom	16	699 0.8×	291 0.9×	267 0.9×	242 0.8×	290 1.4×	58	951
Giri Sulur United States	8	587 0.6×	199 0.6×	159 0.5×	216 0.7×	104 0.5×	19	796
Kris Deprince United States	7	948 1.0×	312 1.0×	252 0.8×	333 1.1×	168 0.8×	15	1.2k
Eren Demirhan United States	8	678 0.7×	231 0.7×	290 0.9×	219 0.7×	201 1.0×	15	955
S. Polyakov Belarus	8	811 0.9×	281 0.9×	180 0.6×	273 0.9×	142 0.7×	20	940
Álvaro Juárez Soto Spain	8	1.1k 1.1×	345 1.1×	222 0.7×	379 1.2×	116 0.6×	44	1.2k
C. Sternberg Italy	16	606 0.7×	228 0.7×	397 1.3×	143 0.5×	210 1.0×	67	1.1k
Alejo Rodríguez‐Vida Spain	18	686 0.7×	263 0.8×	484 1.6×	223 0.7×	359 1.8×	95	1.1k
Erik Briers Belgium	5	1.1k 1.2×	223 0.7×	233 0.8×	445 1.4×	156 0.8×	7	1.3k
Satoshi Fukasawa Japan	17	709 0.8×	122 0.4×	339 1.1×	144 0.5×	183 0.9×	61	929

Countries citing papers authored by Per Rathenborg

Since Specialization

Citations

This map shows the geographic impact of Per Rathenborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Rathenborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Rathenborg more than expected).

Fields of papers citing papers by Per Rathenborg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Rathenborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Rathenborg. The network helps show where Per Rathenborg may publish in the future.

Co-authorship network of co-authors of Per Rathenborg

This figure shows the co-authorship network connecting the top 25 collaborators of Per Rathenborg. A scholar is included among the top collaborators of Per Rathenborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Rathenborg. Per Rathenborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 37(13). 1051–1061. 183 indexed citations

Hussain, Maha, Karim Fizazi, Fred Saad, et al.. (2018). Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine. 378(26). 2465–2474. 677 indexed citations breakdown →

Gulley, James L., Michael Borre, Nicholas J. Vogelzang, et al.. (2018). Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). 5006–5006. 10 indexed citations

Shore, Neal D., Fred Saad, Maha Hussain, et al.. (2018). PD10-09 THE PROSPER TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE. The Journal of Urology. 199(4S). 1 indexed citations

Sternberg, Cora N., Karim Fizazi, Fred Saad, et al.. (2018). Prostate-specific antigen (PSA) response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) treated with enzalutamide (ENZA): Results from PROSPER. European Urology Supplements. 17(2). e868–e869.

Hussain, Maha, Karim Fizazi, Fred Saad, et al.. (2018). PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).. Journal of Clinical Oncology. 36(6_suppl). 3–3. 26 indexed citations

Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2017). Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. The Journal of Urology. 199(2). 459–464. 20 indexed citations

Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2015). Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. European Urology. 68(5). 787–794. 34 indexed citations

Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2014). Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. The Lancet Oncology. 15(6). 592–600. 71 indexed citations

10.

Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2014). Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.. Journal of Clinical Oncology. 32(4_suppl). 62–62. 3 indexed citations

11.

Thomsen, Frederik Birkebæk, et al.. (2014). Biochemical response to enzalutamide therapy in patients with mCRPC following docetaxel and abiraterone treatment.. Journal of Clinical Oncology. 32(4_suppl). 202–202. 4 indexed citations

12.

Thomsen, Frederik Birkebæk, Martin Andreas Røder, Per Rathenborg, et al.. (2013). Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scandinavian Journal of Urology. 48(3). 268–275. 57 indexed citations

13.

Smith, Matthew R., Michael Borre, Per Rathenborg, et al.. (2013). Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).. Journal of Clinical Oncology. 31(15_suppl). 5001–5001. 12 indexed citations

14.

Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2013). Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer.. Journal of Clinical Oncology. 31(6_suppl). 18–18. 4 indexed citations

15.

Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2013). 674 Enzalutamide monotherapy: Results from a phase 2 study in hormone naive prostate cancer patients. European Urology Supplements. 12(1). e674–e675. 1 indexed citations

16.

Barber, Neil, et al.. (2005). Ease of removal of thermo‐expandable prostate stents. British Journal of Urology. 96(4). 578–580. 14 indexed citations

17.

Hauch, Ole, et al.. (1991). Fatal pulmonary embolism associated with surgery. An autopsy study.. PubMed. 156(11-12). 747–9. 20 indexed citations

18.

Hauch, Ole, et al.. (1989). [Presence of pulmonary emboli in Danish autopsy material].. PubMed. 151(21). 1305–7. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact